Introduction
Hematopoietic stem cells self renew and maintain long term repopulation. To fulfill this exceptional capacity for replication, regulated cell proliferation and differentiation, cells must maintain an intact genome. It is inevitable that during the lifetime of a cell, the DNA will accumulate errors from either environmental factors or DNA replication errors.
The complex cellular response to this damage includes cell cycle arrest, transcription induction and DNA repair mechanisms that maintain genomic stability. In the absence of repair, apoptotic pathways lead to cell death, or persistent DNA damage can lead to loss of genetic material, genomic and chromosomal instability, mutagenesis and ultimately malignant transformation or cell death.
DNA methyl adducts are considered some of the most toxic and mutagenic lesions produced by endogenous and environmental methylating agents 1 . One lesion,
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MMR gene defects have been most closely associated with hereditary nonpolyposis colorectal cancer 9 . More recently, MMR mutations and MSI have been identified in hematopoietic malignancies and leukemia and lymphoma cell lines [10] [11] [12] [13] . A low incidence of MSI has been detected in de novo AML and myelodysplastic syndrome 14 and a greater incidence has been reported in secondary and treatment related AML 13, 15 .
Recently, 6 cases of hematologic malignancy have been reported in children homozygous for MMR deficiency 16 due either to MLH1 or MSH2, most of whom also had germline NF-1 mutations. These reports lead to our interest in understanding the role of MMR in hematopoietic stem cell maintenance.
The role of DNA repair processes in the maintenance of the stem cell phenotype, characterized by stem cell longevity and long-term repopulation capacity after DNA damage, has not been evaluated. In studies reported here, we hypothesized that MMR machinery was required for maintenance of stem cell function and that its absence would lead to accumulation of genomic damage and loss of repopulating capacity. For these studies, we used primary murine hematopoietic cells from mice deficient in the mismatch repair gene MSH2-/-, and asked whether they had a selection bias when competed against wild type cells in long term repopulating serial bone marrow transplantation assays.
Because of the known methylation tolerance of MMR defective cells, we evaluated competitive progenitor and stem cell survival with and without in vivo temozolomide (TMZ) exposure. Despite an early survival advantage in vivo, after TMZ, MSH2-/-stem cells exhibited a progressive loss in primary and secondary recipients, leading to bone marrow failure in tertiary recipients associated with an increase in microsatellite instability. These studies suggest that MMR defective progenitors have abnormal
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Methods

Generation of mice
MSH2-/-mice generated in a C57Bl/6 background strain, were kindly provided by T.W.
Mak (Amgen Research Institute, University of Toronto). Mice used for experiments
were generated by interbreeding heterozygotes. The resulting progeny (wild type and homozygous knockout) were used as donor mice.
Serial bone marrow transplants
Bone marrow was flushed from the femur, tibia and pelvis of 6-8 week old wild type or MSH2-/-siblings using RPMI containing 10 U/ml heparin. 2x10 6 
TMZ treatment
TMZ (Drug Synthesis and Chemistry Branch, NCI) was dissolved in 10% DMSO and 90% sterile PBS and used within 10 minutes. Eighty mg/kg was injected i.p. for three consecutive days into mice three weeks after bone marrow transplantation.
Isolation of Sca+Kit+lin-cells
To obtain clonal Sca+kit+/lin-cells, marrow was obtained from mice as described above.
Cells were blocked with normal rat serum for 10 minutes, treated with Fc block (CD16/32, Pharmingen) for 5 minutes then stained with PE conjugated anti-murine lineage markers Ter119, CD3, CD4, CD11b, B220 and APC conjugated anti c-kit and FITC conjugated anti Sca-1 for 20 minutes at 4° C. The appropriate IgG isotype controls (BD-Pharmingen) were performed simultaneously. Sca+Kit+lin-cells were identified in the lineage negative population as those positive for both markers and were sorted as single cells into 96 well plates containing -mem supplemented with m-IL3, m-IL6, rat SCF and spleen cell conditioned medium. Fourteen days later, colonies consisting of greater than 1000 cells were removed from the wells and DNA was isolated for PCR based genotyping.
CFU assay and genotyping
The origin of the colonies derived from both methylcellulose and Sca+kit+ lin-sorting was determined by PCR using primers specific for the MSH2 and neomycin genes and PCR was performed under conditions previously described 17 . 
Cell Cycle analysis
CFU-S assay
C57Bl/6 recipients were lethally irradiated with 850 cGy 57 Co and transplanted with 5x10 4 wild type or MSH2-/-bone marrow mononuclear cells. Twelve days after transplantation, mice were sacrificed and spleens were harvested and fixed with Bouin's.
Colonies were counted using a dissecting microscope.
Telomere Length
The average length of telomere repeat sequences at chromosome ends in individual cells was measured using fluorescence in situ hybridization (FISH) as described 19 
Results
Selection advantage of MSH2-/-bone marrow progenitors
We first evaluated whether TMZ resistant MSH2-/-bone marrow progenitors had a selective advantage in vivo. Mice transplanted with 10% MSH2-/-; 90% wild type marrow were treated with 80mg/kg TMZ x 3 and harvested 8 weeks after transplant.
Enrichment was determined by genotype in both Sca+Kit+lin-cells and methylcellulose progenitors (CFU). We found that MSH2-/-CFU were markedly enriched after drug treatment compared to untreated cells: at 8 weeks, 9 of 92 (9.8%) CFU from seven untreated primary recipients were MSH2-/-, whereas in treated mice MSH2-/-CFU collected from six primary recipients increased ten-fold to 71 of 75 (95%) (p=<.0001, 
Competitive survival of long term repopulating MSH2-/-stem cells
Previous studies have shown that MSH2-/-embryonic fibroblast cells are genomically unstable 17 . This led us to ask whether MSH2-/-hematopoietic progenitor cells would have altered repopulation function, and if so, whether this was related to genomic instability. To expose a defect that might result during stem cell stress, we subjected MSH2-/-hematopoietic cells alone and in competition with normal cells, using a mixture of 10% MSH2-/-and 90% wild type cells, to three serial transplantations.
Marrow cells were transplanted into lethally irradiated recipient mice, sequentially into the first recipient (P1), second recipient (P2), and third recipient (P3) at 8 week intervals.
MSH2-/-cells were 10% of the initial transplant mixture, but in cohorts of mice transplanted sequentially, the proportion of MSH2-/-hematopoietic progenitors recovered in the marrow declined with each transplant. In P1 mice, the percentage of MSH2-/-CFU and Sca+Kit+lin-clones declined to 7 % (n= 98 colonies from 7 mice) and 6.8% (n= 43 colonies from 3 mice), respectively. MSH2-/-CFU decreased further to 1%
(n=36 colonies from 3 mice) in P2 and 0% (n= 60 colonies from 4 mice) in P3 recipient mice (Table 1A) . Sca+Kit+lin-clones also decreased to 0% by P2 (n= 33 colonies from 3 mice).
To exclude the possibility that MSH2-/-cells were lost with sequential transplantation because the absolute number initially transplanted was too few, we transplanted 1x10 6 MSH2-/-cells at 50:50 ratio with wild type cells and evaluated repopulation capacity as above. Similar to the observation in mice transplanted with 10%
MSH2-/-and 90% wild type, an approximate 30 % decline in MSH2-/-cells was observed in bone marrow obtained from P1 mice. P1 marrow contained 32% MSH2-/-CFU (n= 36 colonies from 3 mice) and 26% Sca+Kit+lin-clones (n=18 colonies from 2 mice).CFU from P2 mice reverted to 100% wild type (n= 21 CFU from 2 mice) 8 weeks post transplant and subsequently transplanted mice survived P3 (n= 4) and P4 transplants (n=3) ( Table 1B) . These data indicate that MSH2-/-cells have a repopulation defect and are thus lost during serial transplantation.
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Competitive survival of MSH2-/-long term repopulating cells after TMZ
A different profile was observed in TMZ treated mice subjected to the same serial bone marrow transplant schema because there was initial selection in favor of the MSH2 -/-progenitor cells after TMZ. After serial transplantation, however, we again noted loss of MSH2-/-progenitor and repopulating cells measured as both MSH2-/-CFU and Sca+kit+ lin-clones. As predicted, when the marrow of primary mice recipient of bone marrow transplanted with a mixture of 10% MSH2-/-: 90% wild type cells and treated with TMZ was analyzed 5 weeks after treatment, the proportion of 10% MSH2-/-CFU (75 colonies from 7 mice and Sca+Kit+lin -clones (48 colonies from 4 mice) increased to 95% .When these marrow cells were collected from the primary mice and transplanted into secondary recipients, and these mice treated again with TMZ, the proportion of MSH2 -/-marrow CFU (n= 60 colonies from 4 mice) and Sca+Kit+lin-clones (n= 25 colonies from 2 mice) were maintained at 90% and 80%, respectively (n=4 mice). Thus, with TMZ treatment, it was possible to maintain the selective advantage of the MSH2 -/-cells. However, 12/13 mice transplanted with marrow from P2 recipients that had themselves been repopulated with TMZ treated P1 marrow cells died of bone marrow failure 3 weeks after transplant while mice recipient of marrow from TMZ treated wild type cells survived tertiary (P3) and quaternary (P4) transplants. The one surviving mouse recipient of TMZ treated marrow from the P3 cohort was sacrificed at 8 weeks but the marrow was very hypocellular and produced no CFU after methylcellulose culture so genotyping was not possible. From this we conclude that despite a drug resistance phenotype, TMZ treatment of MSH2-/-cells results in a repopulating defect during sequential transplantation.
We performed similar transplants (P1 through P3) using a mixture of 50% wild type: 50% MSH2-/-marrow cells and TMZ treatment on week three of both P1 and P2 recipients. The CFU in bone marrow harvested from mice 5 weeks after TMZ treatment also increased to 95% MSH2-/-at P1 (n= 30 CFU from 3 mice) and 100% at P2 (n=30 CFU from 2 mice) ( Table 1B) . As above, P3 mice died (n=6 mice) shortly after transplant. These data suggest that mismatch repair defective hematopoietic progenitors have an early selection advantage after TMZ, and appear to replace the marrow of recipients, but develop late stem cell exhaustion which is not observed in wild type cells.
Maintenance of selection advantage of MSH2-/-progenitors
Since our data indicated that MSH2-/-bone marrow cells had a selection advantage in the presence of TMZ, we asked whether repeat selection was necessary to maintain MSH2-/-progenitors.
In two additional cohorts of mice recipient of the 10% MSH2-/-90% wild type mixture, we treated at P1 only and observed for the proportion of MSH2 -/-cells after P2 and P3 transplantation. There was a decrease in MSH2-/-CFU from 95% to 77% by P2 (n=36 colonies from 3 mice) and to 0% by P3 (n=14 mice).
Similarly, mice treated in P2 only resulted in 7% MSH2-/-CFU (n= 101 colonies from 6 mice) [compared to > 90% selection in mice treated during P1] and the genotype reverted to 100% wild type by P3 (n=6 mice) (Data not shown). This suggests that maintenance of MSH2-/-cells is dependent on early and repeated selection with TMZ, but that these cells fail to engraft in the P3 mouse.
Bone Marrow Failure in Tertiary Recipients
Since TMZ treated mice repopulated with MSH2-/-cells in the above experiments did not survive tertiary transplant, we examined hematopoietic engraftment to determine whether they had marrow failure as the cause of death. Mice were initially transplanted with 100% MSH2-/-cells and serial transplant recipients were treated with TMZ at P1 and P2 or left untreated. Tertiary recipients of both cohorts were sacrificed 18 days post transplant. The total number of bone marrow MNCs were not significantly different in treated vs. untreated mice (n=3) (Figure 2A) . However, the number of CFU was 599 per 
Homing of MSH2-/-cells
To investigate whether the repopulating defect was due to abnormal homing of MSH2-/-progenitors, we directly compared bone marrow migration by transplanting figure 4 ).
MSI at the early progenitor cell level was determined in Sca+Kit+lin-clones. As observed above, clones from untreated (n=15) and TMZ treated wild type mice exhibited no MSI in primary (n=17) secondary (n=64) or tertiary (n=26) recipients. However, mice that had been transplanted with MSH2-/-marrow demonstrated 3% (2 of 64) MSI in clones from secondary recipients. These data suggest that bone marrow failure is associated with MSI acquired in vivo in transplanted MSH2-/-cells after TMZ exposure.
Telomere length
Because telomere shortening results in chromosomal instability and could therefore be associated with loss of the stem cell phenotype, we examined the relationship between mismatch repair and telomere maintenance. For these analyses, we used a sensitive flow cytometry FISH method in which an FITC labeled peptide nucleic acid probe was hybridized to telomere repeat sequences. This method has been shown to correlate (r=0.9) with the conventional Southern blot method and is advantageous because it allows analysis of different bone marrow subpopulations 19 .
We found no significant difference in telomere length of low forward and side scatter bone marrow mononuclear cells from untransplanted wild type or MSH2-/-mice.
Measured by flow cytometry FISH, the mean fluorescence intensity (MFI) was 6.5 ± 0.77 for wild type compared to 7.2 ± 0.39 for MSH2-/-cells (n= 2 mice performed in triplicate). (Figure 5A ). Furthermore, the average MFI of cells harvested from untreated secondary recipients transplanted with 100% MSH2-/-cells was 28.4 ± 4.5 (n= 3 mice performed in triplicate) compared to 27.9 ± 4.5 in three mice recipient of MSH2 -/-cells that were then treated with TMZ ( Figure 5B ). It should be noted that comparisons were performed within each experiment and the difference in MFI measurements between the two separate experiments is not indicative of differences in telomere length , but rather instrument variation. Interestingly, TMZ treated MSH2-/-mice had a more heterogeneous telomere length distribution than untreated MSH2-/-in all mice tested (n=4; p=.01, KS test of data in Figure 5B ). Thus, while telomere shortening is not observed in MSH2-/-marrow cells, there is a more subtle redistribution of telomere length after TMZ treatment
Discussion
These data indicate that mismatch repair deficient hematopoietic stem cells acquire microsatellite instability after methylating agent exposure and lose repopulating capacity during the stem cell proliferative stress of sequential transplantation. Since we found no clear difference between wild type and MSH2 -/-progenitor cells in cell cycle distribution, homing or telomere length, we conclude that the stem cell defect is directly attributable to loss of mismatch repair. Thus, long term stem cell maintenance requires Thus, it appears that mismatch repair deficiency results in both a stem cell failure syndrome and increased propensity for malignant transformation. It is even possible that these two conditions are linked. Tables   Table 1A Genotype of CFU harvested from untreated or TMZ treated mice transplanted with 10% MSH2-/-and 90% wild type bone marrow mononuclear cells Table 2 Microsatellite instability in CFU from mice transplanted with either wild type or MSH2-/-bone marrow For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From receiving MSH2-/-cells, however TMZ treated mice had a more heterogeneous distribution of telomere length. In 3 mice tested, there was a significant increase in the breadth of telomere length distribution; p= .01 (K-S test which calculates the difference between the summation of 2 curves). Absolute values of telomere length in A and B cannot be compared because samples were measured separately.
